| 李莲乔,田浴阳,黄倩蕾,齐 琦,李 岩.注射罗格列酮对多发性骨髓瘤小鼠细胞免疫功能与Caspase-3表达的影响[J].现代生物医学进展英文版,2022,(9):1642-1646. |
| 注射罗格列酮对多发性骨髓瘤小鼠细胞免疫功能与Caspase-3表达的影响 |
| Effect of Rosiglitazone Injection on Cellular Immune Function and Caspase-3 Expression in Mice with Multiple Myeloma |
| Received:September 06, 2021 Revised:September 30, 2021 |
| DOI：10.13241/j.cnki.pmb.2022.09.008 |
| 中文关键词: 罗格列酮 多发性骨髓瘤 免疫功能 Caspase-3 炎症因子 体重 |
| 英文关键词: Rosiglitazone Multiple myeloma Immune function Caspase-3 Inflammatory factor Body weight |
| 基金项目:国家癌症中心攀登基金项目（NCC201808B026） |
|
| Hits: 667 |
| Download times: 462 |
| 中文摘要: |
| 摘要 目的：探讨注射罗格列酮对多发性骨髓瘤小鼠细胞免疫功能与Caspase-3表达的影响。方法：多发性骨髓瘤小鼠随机平分为三组-模型组、红细胞组与罗格列酮组，红细胞组与罗格列酮组分别给予经尾静脉注射重组鼠源促红细胞生成素5.0 mg/kg与罗格列酮5 mg/kg 100 μL，模型组给予尾静脉注射等体积生理盐水，每天给药1次，检测细胞免疫功能与Caspase-3表达变化情况。结果：三组治疗第7 d与治疗第14 d的肿瘤体积高于治疗第1 d(P<0.05)，红细胞组与罗格列酮组低于模型组(P<0.05)，罗格列酮组低于红细胞组(P<0.05)。红细胞组与罗格列酮组治疗第7 d与治疗第14 d的血清白介素(Interleukin，IL)-6与肿瘤坏死因子(Tumor necrosis factor，TNF)-α水含量低于模型组(P<0.05)，罗格列酮组低于红细胞组(P<0.05)。红细胞组与罗格列酮组治疗第14 d与治疗第28 d的脾脏B淋巴细胞、T淋巴细胞比例对比高于模型组(P<0.05)，罗格列酮组高于红细胞组(P<0.05)。红细胞组与罗格列酮组治疗第14 d与治疗第28 d的脑黑质Caspase-3蛋白表达水平低于模型组(P<0.05)，罗格列酮组低于红细胞组(P<0.05)。结论：注射罗格列酮在多发性骨髓瘤小鼠的应用能改善细胞免疫功能，抑制脑黑质Caspase-3的表达，同时也能促进小鼠体重恢复，抑制炎症因子的表达。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of rosiglitazone injection on cellular immune function and Caspase-3 expression in mice with multiple myeloma. Methods: Multiple myeloma mice were randomly divided into three groups-model group, red blood cell group and rosiglitazone group. The red blood cell group and rosiglitazone group were given tail vein injection of recombinant mouse erythropoietin 5.0 mg/kg and rosiglitazone 5 mg/kg 100 μL, the model group were given equal volume of normal saline via tail vein injection, once a day, the cellular immune function and Caspase-3 expression changes were detected. Results: The tumor volume on the 7th and 14th day of treatment in the three groups were higher than that on the 1st day of treatment(P<0.05), the red blood cell group and rosiglitazone group were lower than the model group(P<0.05), and the rosiglitazone group were lower than the red blood cell group (P<0.05). The serum levels of interleukin (IL)-6 and tumor necrosis factor (TNF)-α in the red blood cell group and rosiglitazone group on the 7th and 14th day of treatment were lower than those of the model group(P<0.05), the rosiglitazone group were lower than the red blood cell group(P<0.05). The ratio of splenic B lymphocytes and T lymphocytes on the 14th day and 28th day of treatment between the red blood cell group and the rosiglitazone group were higher than that of the model group(P<0.05), and the rosiglitazone group were higher than the red blood cell group (P<0.05). The expression of Caspase-3 protein in the substantia nigra of the erythrocyte group and rosiglitazone group were lower on the 14th and 28th day of treatment than the model group (P<0.05), and the rosiglitazone group were lower than that of the red blood cell group(P<0.05). Conclusion: The application of rosiglitazone injection in multiple myeloma mice can improve cellular immune function and inhibit the expression of Caspase-3 in the substantia nigra of the brain. At the same time, it can also promote the weight recovery of mice and inhibit the expression of inflammatory factors. |
|
View Full Text
View/Add Comment Download reader |
| Close |
